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EditorialKeeping an Eye on Our Moral CompassThis editorial covers two topics, both of which I have been plan-
ning to write about for a while. Over the past few weeks, some of
the issues involved have been thrown into sharp focus by the
tragic and untimely death of Yoshiki Sasai. I am sure I am not
alone in still being deeply shocked and saddened by this unex-
pected turn of events. The vast majority of us will never know
about, let alone understand, the combination of factors and cir-
cumstances that led Yoshiki to make such a decision. We can
nevertheless all take a collective moment to honor him for the
major contributions he made and to reflect on what we can learn
from the overall situation about how we conduct the research
enterprise.
The first issue, which has probably already sprung to mind for
many of you after that opening, is research misconduct. The
whole topic of the STAP papers, the concerns about them, and
their eventual retraction has been covered in great detail in
many outlets already, and I will not rehash it here. There is un-
doubtedly also a lot more information underlying the institutional
and journal examination of the issues involved than is evident
from the public discussions. From my experience as an editor,
I know that investigation of concerns about papers can be
complicated, and expectations of rapid resolution are frequently
unrealistic. In some cases, where there is clear evidence that
data have been manipulated, retraction is really the only appro-
priate option. Retraction can also be called for if the errors are
not actively intentional and could have been avoided by greater
care in figure assembly but nevertheless are sufficiently exten-
sive to mean that they undermine confidence in the conclusions
of the paper. In many cases, however, errors resulting from mis-
takes in figure preparation are relatively minor and, while regret-
table, do not necessitate retraction of the paper involved. There
is an example of this last type of situation in the Erratum we are
publishing this month.
Concerns about high-profile papers inevitably raise questions
about what journals can or should do to avoid allowing problem-
atic data to be published in the first place. At the outset, as jour-
nal editors we approach all of the research that we read from an
initial position of trust, because the vast majority of researchers
working in this and any field do so honestly and report their re-
sults accurately. Nevertheless, problems can and sometimes
do arise. Many are picked up by reviewers and addressed as
part of the peer review process. Others can be identified by
figure screening programs that many publishers, including Cell
Press, are working on or already have in place. We and other
publishers are also looking at ways to increase the accuracy of
reporting to assist with reproducibility and the quality of underly-
ing experimental design. These approaches are useful, but they
have limitations, and they are not sufficiently sophisticated to
detect all of the different types of issues that can occur. The
community has other checks and balances in place that come
into play after publication, and in the digital age these have
expanded from personal discussions and conference sessions
to blogs, comments, and tweets in the online environment.
Prominent studies in particular are often the subject of detailed
examination and criticism. In the aftermath of Yoshiki’s death,there have been many comments about the tone of the discus-
sions among scientists and in the general media regarding the
STAP papers and other cases. There are some powerful under-
lying messages about civility toward each other and about being
understanding of the fact that even the most rigorous of
scientists can make mistakes, either personally or via their
colleagues. Journal editors are not infallible either. If errors are
corrected quickly and appropriately, we should all be able to
move on. I hope that in the future we will learn as a community
to handle such situations more effectively by combining the
necessary adherence to high scientific standards, and corrective
action when they are not met, with compassion for the people
involved.
The second topic that I would like to address is clinical trans-
lation. It goes without saying that many of us working in or sup-
porting the stem cell field are excited about clinical translation
as a major long-term, and in some cases even quite proximal-
term, goal. There are many examples in the literature of strong
underlying research leading toward new translational outcomes
that involve either cell-based therapies or new treatment ap-
proaches discovered using stem cells. Yoshiki Sasai himself
had supported one such effort by working with colleagues at
the RIKEN CDB on underlying research that set the stage for
clinical testing of a treatment for macular degeneration using
iPSC-derived retinal sheets. This overall trend was very
apparent at the ISSCR annual meeting earlier this year, where
one of the most exciting sessions focused on clinical transla-
tion. At that meeting, I was also very happy to learn that the
ISSCR are working to update the guidelines and resources
that they make available for patients. As Tim Caulfield and col-
leagues outline in their Forum article in this issue, such efforts
are sorely needed. Despite all of these positive developments,
there are still companies and organizations that are promoting
stem-cell-based therapies in ways that seem to many in the field
to be premature and even dangerous. There are also still too
many stories about patients being asked to pay large sums of
money for treatments that have minimal scientific support. As
a journal, our goal is to promote rigorous, well-controlled under-
lying research and its progress toward clinical translation, with
both safety and efficacy as key considerations in that regard.
This approach reflects our perspective on what we see as being
the most effective path forward for the community as well.
Neither the field nor the patients will benefit if enthusiasm about
commercial application of stem cell research runs ahead of sci-
entific rigor. I hope that through positive examples and commu-
nication initiatives we will all be able to address the troublesome
issues in this area more effectively as well and again with
compassion and understanding alongside a strong focus on
high-quality science.
I would like to end this piece with some memories of Yoshiki
Sasai. I personally did not know Yoshiki particularly well, but
had of course interacted with him scientifically in a variety of con-
texts. He supported Cell Stem Cell through being a member of
the editorial board and through submitting to and reviewing for
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Editorialenthusiasm for his own work and that of others, his excitement
when sharing his vision for 3D organogenesis, and his optimism
about the clinical translation partnership between the RIKEN
CDB and the Institute for Biomedical Research and Innovation.
Many of these traits are also reflected in Arnold Kriegstein’s
thoughtful tribute to him, which appears in this issue. Yoshiki256 Cell Stem Cell 15, September 4, 2014 ª2014 Elsevier Inc.was a fantastic contributor to the stem cell field, and it is a signif-
icant loss for all of us that he is no longer here.
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